Open AccessSevere Diarrhea in the Setting of Immune Checkpoint Inhibitors
Author(s) -
Jean Kuo,
Amy Davis,
Eduardo A. Rodríguez,
Marcelo F. Vela,
Russell I. Heigh,
Marcela Salomao,
Suryakanth R. Gurudu
Publication year - 2018
Publication title -
case reports in gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.247
H-Index - 18
ISSN - 1662-0631
DOI - 10.1159/000493183
Subject(s) - ipilimumab , medicine , nivolumab , diarrhea , colitis , immune system , adverse effect , gastrointestinal tract , immunology , immune checkpoint , immunotherapy
Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by enhanced T cell activation. Immune-related adverse events (irAEs) commonly occur with ICPI use and can affect multiple organ systems including the gastrointestinal tract. Due to irAEs, the use of ICPIs is limited in autoimmune diseases. We present a case of microscopic colitis diagnosed after the initiation of nivolumab and a case of ipilimumab colitis and Clostridium difficile in the setting of Crohn’s colitis.